Phase 2 Triple-Negative Breast Cancer Clinical Trials
20 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 20 trials
Recruiting
Phase 2
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Breast CancerTNBC - Triple-Negative Breast Cancer
Stephen Shiao35 enrolled1 locationNCT05491226
Recruiting
Phase 2
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 2
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
TNBC - Triple-Negative Breast CancerEarly Stage Triple-Negative Breast CarcinomaTNBC
Cedars-Sinai Medical Center34 enrolled4 locationsNCT07017673
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 1Phase 2
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 2
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Recurrent Triple-Negative Breast Cancer
Yukinori Ozaki44 enrolled15 locationsNCT06976944
Recruiting
Phase 1Phase 2
Saci Nivo Rela for TNBC
Metastatic Triple-negative Breast Cancer
Yale University60 enrolled1 locationNCT06963905
Recruiting
Phase 2
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
TNBC - Triple-Negative Breast Cancer
First Affiliated Hospital of Zhejiang University37 enrolled2 locationsNCT07351487
Recruiting
Phase 2
Triple Negative Breast Cancer and Celecoxib. Pilot Study
Triple-Negative Breast Cancer
Université de Sherbrooke30 enrolled1 locationNCT07104266
Recruiting
Phase 2
PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.
TNBC - Triple-Negative Breast Cancer
Jules Bordet Institute20 enrolled1 locationNCT06059469
Recruiting
Phase 2
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Breast CancerHER2-negative Breast CancerTNBC - Triple-Negative Breast Cancer
Processa Pharmaceuticals90 enrolled13 locationsNCT06568692
Recruiting
Phase 2
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital138 enrolled1 locationNCT06878625
Recruiting
Phase 1Phase 2
Study of LP-184 in Patients With Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid TumorTNBC - Triple-Negative Breast Cancer+4 more
Lantern Pharma Inc.175 enrolled9 locationsNCT05933265
Recruiting
Phase 2
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
Metastatic Triple-negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University60 enrolled1 locationNCT06851299
Recruiting
Phase 2
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.160 enrolled1 locationNCT06492005
Recruiting
Phase 2
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
Advanced Triple-Negative Breast Cancer
BeBetter Med Inc120 enrolled2 locationsNCT06685796
Recruiting
Phase 2
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
TNBC - Triple-Negative Breast Cancer
Fudan University74 enrolled1 locationNCT06387628
Recruiting
Phase 2
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
TNBC - Triple-Negative Breast Cancer
Huihua Xiong78 enrolled1 locationNCT06125080
Recruiting
Phase 2
Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer
TNBC - Triple-Negative Breast Cancer
The First Affiliated Hospital with Nanjing Medical University60 enrolled1 locationNCT05834582
Recruiting
Phase 1Phase 2
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
Triple-Negative Breast Cancer
Jiangxi Provincial Cancer Hospital20 enrolled1 locationNCT04481763